MDS ePoster Library

Debate: Lenalidomide is the standard of care for the management of isolated del 5(q) MDS
. Jadersten M. 05/20/11; 7656 Disclosure(s): Celgene: participation in advisory board meeting 2009
Dr. Martin Jadersten
Dr. Martin Jadersten
All contributions
Biography
Login now to access Regular content available to all registered users.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
Critical evaluation of the role of treatment with lenalidomide in myelodysplastic syndromes with del(5q)
Code of conduct/disclaimer available in General Terms & Conditions

About Us

More than 11,000 clinicians, scientists and other healthcare professionals dedicated to improving care for some of the most challenging disorders through education and research.
2025 ©
International Congress of Parkinson's Disease and Movement Disorders
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies